PDF DatasheetHuman, Monkey, Mouse, and Rat Anti-Cyclin D1 Antibody Product Attributes
Species: Human, Monkey, Mouse, and Rat
Tested Applications: Flow Cytometry, Immunofluorescence, Western Blot, Immunohistochemistry (IHC).
Application Notes: Flow Cytometry (0.5-1ug of antibody/million cells in 0.1ml), Immunofluorescence (1-2ug of antibody/ml), Western Blot (0.5-1ug of antibody/ml), Immunohistochemistry (IHC) (Formalin-fixed) (0.5-1ug of antibody/ml for 30 minutes at RT)
Clonality: Monoclonal
Anti-Cyclin D1 Antibody Clone: SPM587
Clone SPM587 Host and Isotype: Mouse IgG2a kappa
Anti-Human, Monkey, Mouse, and Rat Cyclin D1 Positive Control Sample: T47D, ZR75, BT474, SKBR3, MCF-7, MDA-MB-453, HT29, Ramos, Jurkat or A431 cells. ~60% of mantle cell lymphomas, ~40% of breast carcinomas are positive.
Cellular Localization of Antibody Nuclear
Buffer and Stabilizer: 10mM PBS with 0.05% BSA & 0.05% azide.
Antibody Concentration: 200ug/ml
Antibody Purification Method:Protein A/G Purified
Immunogen: Human recombinant full length cyclin D1 protein
Storage Conditions: Store at 2 to 8° C (refrigerate). Stable for 24 months when properly stored.
Cyclin D1 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-CCND1 antibody staining is expected to be primarily localized to the nucleoplasm. There is variability in either the signal strength or the localization of signal in nucleoplasm from cell to cell.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Cyclin D1 expression as measured by anti-Cyclin D1 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | + | + | – | – | – | – | + | + | + | – | + | – | – | + | + | + | + | – | + | – |
| CCND1 Variability | +++ | ++ | + | ++ | + | + | ++ | +++ | ++ | ++ | ++ | ++ | ++ | +++ | ++ | ++ | ++ | + | ++ | ++ |
| Cyclin D1 General Information | |
|---|---|
| Alternate Names | |
| Cyclin-D1CCND1 | |
| Molecular Weight | |
| 36kDa | |
| Chromosomal Location | |
| 11q13.2 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | CCND1 |
| Entrez Gene ID | 595 |
| Ensemble Gene ID | ENSG00000110092 |
| RefSeq Protein Accession(s) | NP_444284 |
| RefSeq mRNA Accession(s) | NM_053056, |
| RefSeq Genomic Accession(s) | NC_000011, NC_018922, NG_007375 |
| UniProt ID(s) | Q6FI00, P24385 |
| UniGene ID(s) | Q6FI00, P24385 |
| HGNC ID(s) | 1582 |
| Cosmic ID(s) | CCND1 |
| KEGG Gene ID(s) | hsa:595 |
| PharmGKB ID(s) | PA75 |
| General Description of Cyclin D1. | |
| Recognizes a protein of 36kDa, identified as cyclin D1. Cyclin D1, one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. This antibody neutralizes the activity of cyclin D1 in vivo. About 60% of mantle cell lymphomas (MCL) contain a t(11; 14)(q13; q32) translocation resulting in over-expression of cyclin D1. This antibody is useful in identifying mantle cell lymphomas (cyclin D1 positive) from CLL/SLL, follicular lymphomas (cyclin D1 negative). Occasionally, hairy cell leukemia, plasma cell myeloma weakly express Cyclin D1. | |
Limitations and Warranty
enQuire Bio’s Cyclin D1 Anti-Human Monoclonal is available for Research Use Only. This antibody is guaranteed to work for a period of two years when properly stored.
There are no reviews yet.